SG/CALL/MODERNA/140/0.1/20.12.24 | Market Closed - Deutsche Boerse AG 03:51:39 2024-05-10 pm EDT | ||
| 1.17 EUR | -18.75% |
|
| Current month | +8.33% | ||
| 1 month | +15.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.17 | -18.75% | 0 |
| 24-05-09 | 1.44 | +4.35% | 0 |
| 24-05-08 | 1.38 | +2.99% | 0 |
| 24-05-07 | 1.34 | -2.19% | 0 |
| 24-05-06 | 1.37 | -12.18% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 10, 2024 at 03:51 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SV459G |
| ISIN | DE000SV459G9 |
| Date issued | 2023-05-09 |
| Strike | 140 $ |
| Maturity | 2024-12-20 (223 Days) |
| Parity | 10 : 1 |
| Emission price | 3.66 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.86 € |
|---|---|
| Lowest since issue | 0.39 € |
| Spread | 0.01 € |
| Spread % | 0.85% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.3
USD
Average target price
139.4
USD
Spread / Average Target
+18.79%
- Stock Market
- Warrants
- Warrant
